Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 4:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Protamine Clear all
Not listed No phase listed Observational

Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin

NCT04034524
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GLP-1 receptor agonist, Insulin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Sep 3, 2026, 4:19 PM EDT
Completed Phase 3 Interventional Results available

A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma

NCT00139659
View directory record Official record
Conditions
Asthma, Diabetes Mellitus
Interventions
Inhaled Insulin, Subcutaneous Insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 77 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
86
States / cities
Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2010 · Synced Sep 3, 2026, 4:19 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes

NCT00487240
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin Lispro Protamine Suspension, Insulin Levemir
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Idaho Falls, Idaho • Springfield, Illinois • Topeka, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2010 · Synced Sep 3, 2026, 4:19 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon

NCT00694122
View directory record Official record
Conditions
Type 1 Diabetes, Dawn Phenomenon
Interventions
Lantus (glargine)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2014 · Synced Sep 3, 2026, 4:19 PM EDT
Completed Phase 3 Interventional

Optimal Heparin Dosing Regimens for Cardiopulmonary Bypass

NCT00587444
View directory record Official record
Conditions
Postoperative Hemorrhage
Interventions
Heparin, HH or high heparin, heparin concentration HC
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2009 · Synced Sep 3, 2026, 4:19 PM EDT
Terminated Not applicable Interventional Results available

Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH

NCT00564018
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Insulin detemir, Glargine, NPH
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
6 Years to 18 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Sep 3, 2026, 4:19 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

NCT01798706
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Lixisenatide (AVE0010), Placebo, Antidiabetic background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
70 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
14
States / cities
La Jolla, California • Norwalk, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 3, 2026, 4:19 PM EDT
Completed Early Phase 1 Interventional

Validation of Insulin Protocol for Glucocorticoid-induced Hyperglycemia in Diabetic Oncology Patients

NCT02012465
View directory record Official record
Conditions
Lymphoma, Diabetes Mellitus, Type 2, Hyperglycemia
Interventions
Insulin protocol
Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Sep 3, 2026, 4:19 PM EDT
Completed Phase 3 Interventional

Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes

NCT00097877
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
biphasic insulin aspart, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
71
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Vestavia Hills, Alabama + 59 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Sep 3, 2026, 4:19 PM EDT
Completed Phase 3 Interventional Results available

6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes

NCT00993473
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin glargine (HOE901), Neutral Protamine Hagedorn (NPH) insulin, Insulin lispro
Drug
Lead sponsor
Sanofi
Industry
Eligibility
1 Year to 6 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
Sacramento, California • San Diego, California • Greenwood Village, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2012 · Synced Sep 3, 2026, 4:19 PM EDT
Completed Phase 4 Interventional Results available

Use of Protamine for Heparin Reversal After Catheter Ablation of Atrial Fibrillation

NCT03140631
View directory record Official record
Conditions
Atrial Fibrillation, Catheter Ablation
Interventions
Protamine Sulfate
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Sep 3, 2026, 4:19 PM EDT
Terminated Phase 3 Interventional Results available

A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With COPD

NCT00138671
View directory record Official record
Conditions
Diabetes Mellitus, Chronic Obstructive Pulmonary Disease
Interventions
Subcutaneous Insulin, Inhaled Insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 77 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
77
States / cities
Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2010 · Synced Sep 3, 2026, 4:19 PM EDT
Terminated Phase 3 Interventional Results available

A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin

NCT02131272
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Insulin detemir, Insulin NPH, Diet/exercise
Drug · Behavioral
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
10 Years to 18 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Sep 3, 2026, 4:19 PM EDT
Withdrawn No phase listed Observational

The Role of Tranexamic Acid in Reducing Blood Transfusion Requirements After Cardiopulmonary Bypass in Neonates

NCT01914211
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Tranexamic Acid, Acute Normovolemic Hemodilution
Drug · Procedure
Lead sponsor
Aymen N Naguib
Other
Eligibility
Up to 28 Days
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Sep 3, 2026, 4:19 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Comparative Bioequivalence Study of Wockhardt's Insulin Analogue Listro Mix 50/50® and Humalog Mix50/50® in Healthy Subjects

NCT01400789
View directory record Official record
Conditions
Bioequivalence in Healthy Subjects
Interventions
Insulin Lispro
Biological
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Sep 3, 2026, 4:19 PM EDT
Recruiting Phase 2 Interventional

DETERMINE: Detemir vs NPH

NCT05124457
View directory record Official record
Conditions
Gestational Diabetes, Diabetes Mellitus, Type 2
Interventions
Insulin Detemir, Insulin NPH
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Sep 3, 2026, 4:19 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Comparative Bioequivalence Study of Wockhardt's Insulin Analogue Mixture Listro Mix 75/25® and Humalog Mix75/25 ® in Healthy Subjects

NCT01400802
View directory record Official record
Conditions
Bioequivalence in Healthy Subjects
Interventions
Insulin Lispro
Biological
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Sep 3, 2026, 4:19 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide

NCT00560417
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Lispro Protamine Suspension, Insulin Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 74 Years
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
49
States / cities
Phoenix, Arizona • Concord, California • Escondido, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2011 · Synced Sep 3, 2026, 4:19 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE)

NCT00510952
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Lispro Protamine Suspension, Insulin Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
11
States / cities
Jonesboro, Arkansas • Huntington Park, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2010 · Synced Sep 3, 2026, 4:19 PM EDT
Completed Phase 3 Interventional

Comparing Angiomax to Heparin With Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB)

NCT00079586
View directory record Official record
Conditions
Cardiovascular Disease, Coronary Artery Bypass Surgery
Interventions
Heparin, Bivalirudin
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 4, 2012 · Synced Sep 3, 2026, 4:19 PM EDT
Completed Phase 4 Interventional Results available

Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia

NCT01184014
View directory record Official record
Conditions
Hyperglycemia
Interventions
NPH insulin plus Complete Insulin Orders, Complete Insulin Orders
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Saint Louis Park, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Sep 3, 2026, 4:19 PM EDT
Completed Phase 3 Interventional

Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.

NCT00313001
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
biphasic insulin aspart, exenatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Plainsboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Sep 3, 2026, 4:19 PM EDT
Completed Phase 4 Interventional Results available

Insulin Glargine "All to Target" Trial

NCT00384085
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Glulisine, Insulin Glargine, Premixed Insulin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
30 Years to 80 Years
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 5, 2011 · Synced Sep 3, 2026, 4:19 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY)

NCT00494013
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Insulin Lispro Protamine Suspension, Detemir
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
27
States / cities
Hueytown, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2009 · Synced Sep 3, 2026, 4:19 PM EDT